Tadataka Yamada
Senior Entrepreneur in Residence @ Frazier Healthcare Partners
Tadataka Yamada is a Series A investor at Frazier Healthcare Partners focused on Wellness and Health Care. Tadataka (Tachi) Yamada, MD, is the ard Chief Medical and Scientific Officer of Takeda Pharmaceuticals. In this capacity, he serves as a science and medical advisor to the CEO and chairs the Corporate Management Operating Committee, which oversees all investments in research and development, business development, and in-licensing.He is also theSenior Entrepreneur in Residence at Frazier Healthcare. In this role, he supports Frazier Healthcare’s venture and growth equity activities. Dr. Yamada was formerly the president of the Bill & Melinda Gates Foundation Global Health Program.Before joining the Gates Foundation, he was the chairman for research and development and a member of the board of directors for GlaxoSmithKline. Dr. Yamada was born in Japan and completed his education in the United States.He graduated from Stanford University with a bachelor of arts in history and obtained his doctor of medicine from the New York University School of Medicine. After completing his internal medicine training at the Medical College of Virginia, he became an investigator in the United States Army Medical Research Institute of Infectious Diseases, trained in gastroenterology at the University of California, Los Angeles, School of Medicine and assumed his first faculty position there. He later moved to the University of Michigan, where he ultimately became chairman of the Department of Internal Medicine and physician-in-chief of the University of Michigan Medical Center before joining GlaxoSmithKline.
- Total investments:
- 1
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Tadataka Yamada invests in
Stages Tadataka Yamada invests in
Countries Tadataka Yamada invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Wellness 1 (100%)
- Health Care 1 (100%)
- Therapeutics 1 (100%)
- Biotechnology 1 (100%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Passage Bio is a fully integrated gene therapy company with a mission to develop a portfolio of five life-transforming AAV-delivered therapeutics for the treatment of rare monogenic central nervous system diseases. The company is based in Philadelphia, PA and has a research, collaboration and license agreement with the University of Pennsylvaniaand its Gene Therapy Program (GTP) as well as the Orphan Disease Center (ODC). Pursuant to the research collaboration, GTP conducts IND-enabling preclinical work, and Passage Bio is responsible for clinical development, regulatory, manufacturing and commercialization of all product candidates. The ODC is responsible for natural history studies, KOL engagement, and patient advocacy outreach. | $115.5M / Series A / Feb 15, 2019 |
Co-Investors
Founded in 1991, Frazier Healthcare Partners is a leading provider of growth capital to healthcare companies. The firm has over $2B under management and has made investments in over 170 healthcare companies, with investment types ranging from company creation and venture capital to growth buyouts and leveraged recapitalizations.Frazier’sexperienced team takes an active approach to helping build portfolio companies, leveraging the team’s deep domain expertise and expansive network of healthcare executives, advisors, and industry thought leaders. The firm’s Growth Buyout team invests in profitable companies focusing on healthcare services, pharmaceutical services, medical products, and related sectors. The firm’s Life Sciences team invests in therapeutics and related areas that are addressing unmet medical needs through innovation.
Frazier Healthcare Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Nathan Every
General Partner
|
|||
Patrick Heron
General Partner
|
|||
|
Tadataka Yamada
Senior Entrepreneur in Residence
|
|||
Alan D. Frazier
Managinig Partner, Founder & Chairman
|
|||
Bob Baltera
Entrepreneurs In Residence
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Tadataka Yamada invest in?
Tadataka Yamada invests primarily in Wellness, Health Care and Therapeutics startups, most often at Series A stage. Most of the 1 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Tadataka Yamada?
Public channels for Tadataka Yamada include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Tadataka Yamada last invest?
The most recent investment recorded for Tadataka Yamada closed in Feb 2019. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
